Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Lakewood-Amedex Biotherapeutics Inc (LABT)

Lakewood-Amedex Biotherapeutics Inc (LABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum PR Newswire - Tue Jun 16, 7:02AM CDT

SARASOTA, Fla. , June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc. , (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent,...

LABT : 0.4100 (-31.92%)
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers PR Newswire - Wed May 27, 7:02AM CDT

Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patents

LABT : 0.4100 (-31.92%)
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers PR Newswire - Mon May 18, 7:02AM CDT

Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial

LABT : 0.4100 (-31.92%)
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 PR Newswire - Tue May 12, 7:02AM CDT

Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU market

LABT : 0.4100 (-31.92%)
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors PR Newswire - Tue Apr 28, 6:33AM CDT

Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing

LABT : 0.4100 (-31.92%)
ENVB : 1.2900 (-0.77%)
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT" PR Newswire - Thu Apr 23, 9:42AM CDT

SARASOTA, Fla. , April 23, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc. , (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum...

LABT : 0.4100 (-31.92%)

Barchart Exclusives

Citi Initiates Bullish Coverage on Figma Stock as the AI Monetization Story Takes Shape Barchart - 2 minutes ago
Citi analysts signal a "Buy" rating on Figma, expecting AI monetization to outweigh risks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.